Skip to main content

Home/ Dr. Goodyear/ Group items matching "low-dose" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Temperature-dependent and time-dependent effects of hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3: in vitro studies - PMC - 0 views

www.ncbi.nlm.nih.gov/...PMC4346362

hyperthermia

shared by Nathan Goodyear on 18 Apr 23 - No Cached
  • Nathan Goodyear on 18 Apr 23
     
    effect of time and temperature on the viability of melanoma cell lines and expression of HSP 70 & 90 after brief exposure to hyperthermia. While hyperthermia has multiple mechanisms of action, this paper elucidates two essential benefits of high-dose hyperthermia. First, the study illustrates why high-dose hyperthermia treatments (45°C - 47°C) are so much more effective than the low-dose hyperthermia (39°C - 43°C) produced by commercially available heating devices.
Nathan Goodyear

Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies | Cancer Research - 0 views

cancerres.aacrjournals.org/...6717

low-dose chemotherapy cancer metronomic chemotherapy

shared by Nathan Goodyear on 03 Jul 20 - No Cached
  • Nathan Goodyear on 03 Jul 20
     
    In many ways, it can be said that low-dose metronomic chemotherapy outperforms maximum tolerated chemotherapy.
Nathan Goodyear

http://onlinelibrary.wiley.com/store/10.1002/hep.21080/asset/21080_ftp.pdf;jsessionid=C45939E71FD1E43279D6DC7447C7FC1A.f04t01?v=1&t=hrgzlf7k&s=06a20991c511bb972b76d7ad9ed62c56370452a3 - 0 views

onlinelibrary.wiley.com/...FD1E43279D6DC7447C7FC1A.f04t01

vitamin C IV vitamin C IV intravenous cirrhosis

shared by Nathan Goodyear on 10 Feb 14 - No Cached
  • Nathan Goodyear on 10 Feb 14
     
    small study looked at patients with liver cirrhosis.  The authors used a low dose of IV vitamin C (5 grams) and found that this improved endothelial dysfunction.  Patients with cirrhosis were found to be low in vitamin C.  The IV vitamin C was well tolerated, despite a low dose.
Nathan Goodyear

Testosterone Deficiency, Cardiac Health, and Older Men - 0 views

www.hindawi.com/...143763

low T Testosterone obesity type II diabetes diabetes health wellness metabolic syndrome lipids cholesterol hypogonadism TDS testicular dysgenesis syndrome men male hormone hormones prostate cancer

shared by Nathan Goodyear on 12 May 14 - No Cached
  • Studies have shown pharmacological doses of testosterone to relax coronary arteries when injected intraluminally [39] and to produce modest but consistent improvement in exercise-induced angina and reverse associated ECG changes [40]. The mechanism of action is via blockade of calcium channels with effect of similar magnitude to nifedipine
    • Nathan Goodyear
      Nathan Goodyear on 12 May 14
       
      This directly refutes the recent studies (3) that Testosterone therapy increases cardiovascular events.
    • Nathan Goodyear
      Nathan Goodyear on 13 May 14
       
      Testosterone acts as a calcium channel blocker inducing vasodilation.
  • men with chronic stable angina pectoris, the ischaemic threshold increased after 4 weeks of TRT and a recent study demonstrates improvement continuing beyond 12 months [
  • Exercise capacity in men with chronic heart failure increased after 12 weeks
  • ...36 more annotations...
  • Studies have shown an inverse relationship between serum testosterone and fasting blood glucose and insulin levels
  • Medications such as chronic analgesics, anticonvulsants, 5ARIs, and androgen ablation therapy are associated with increased risk of testosterone deficiency and insulin resistance
  • Women with T2D or metabolic syndrome characteristically have low SHBG and high free testosterone
    • Nathan Goodyear
      Nathan Goodyear on 12 May 14
       
      This stands in polar opposite of that with men.
  • Hypogonadism is a common feature of the metabolic syndrome
  • The precise interaction between insulin resistance, visceral adiposity, and hypogonadism is, as yet, unclear but the important mechanisms are through increased aromatase production, raised leptin levels, and increase in inflammatory kinins
  • levels of testosterone are reduced in proportion to degree of obesity
  • Men should be encouraged to combine aerobic exercise with strength training. As muscle increases, glucose will be burned more efficiently and insulin levels will fall. A minimum of 30 minutes exercise three times weekly should be advised
  • Testosterone increases levels of fast-twitch muscle fibres
  • By increasing testosterone, levels of type 2 fibres increase and glucose burning improves
  • Weight loss will increase levels of testosterone
  • studies now clearly show that low testosterone leads to visceral obesity and metabolic syndrome and is also a consequence of obesity
  • In the case of MMAS [43], a baseline total testosterone of less than 10.4 nmol/L was associated with a greater than 4-fold incidence of type 2 diabetes over the next 9 years
  • There is high level evidence that TRT improves insulin resistance
  • Low testosterone predicts increased mortality and testosterone therapy improves survival in 587 men with type 2 diabetes
  • A similar retrospective US study involved 1031 men with 372 on TRT. The cumulative mortality was 21% in the untreated group versus 10% ( ) in the treated group with the greatest effect in younger men and those with type 2 diabetes
  • the presence of ED has been shown to be an independent risk factor, particularly in hypogonadal men, increasing the risk of cardiac events by over 50%
  • A recent online publication on ischaemic heart disease mortality in men concluded optimal androgen levels are a biomarker for survival
  • inverse associations between low TT or FT (Table 2) and the severity of CAD
  • A recent 10 year study from Western Australia involving 3690 men followed up from 2001–2010 concluded that TT and FT levels in the normal range were associated with decreased all-cause and cardiovascular mortality, for the first time suggesting that both low and DHT are associated with all-cause mortality and higher levels of DHT reduced cardiovascular risk
  • TDS is associated with increased cardiovascular and all-cause mortality
  • The effect of treatment with TRT reduced the mortality rate of treated cohort (8.4%) to that of the eugonadal group whereas the mortality for the untreated remained high at 19.2%
  • hypogonadal men had slightly increased triglycerides and HDL
  • Men with angiographically proven CAD (coronary artery disease) have significantly lower testosterone levels [29] compared to controls ( ) and there was a significant inverse relationship between the degree of CAD and TT (total testosterone) levels
  • TRT has also been shown to reduce fibrinogen to levels similar to fibrates
  • men treated with long acting testosterone showed highly significant reductions in TC, LDL, and triglycerides with increase in HDL, associated with significant reduction in weight, BMI, and visceral fat
  • Low androgen levels are associated with an increase in inflammatory markers
  • In the Moscow study, C-reactive protein was reduced by TRT at 30 weeks versus placebo
  • In some studies, a decline in diastolic blood pressure has been observed, after 3–9 months [24, 26] and in systolic blood pressure
  • A decline was noted in IL6 and TNF-alpha
  • No studies to date show an increase in LUTS/BPH symptoms with higher serum testosterone levels
  • TRT has been shown to upregulate PDE5 [65] and enhance the effect of PDE5Is (now an accepted therapy for both ED and LUTS), it no longer seems logical to advice avoidance of TRT in men with mild to moderate BPH.
    • Nathan Goodyear
      Nathan Goodyear on 12 May 14
       
      What about just starting with normalization of Testosterone levels first.
  • Several meta-analyses have failed to show a link between TRT and development of prostate cancer [66] but some studies have shown a tendency for more aggressive prostate cancer in men with low testosterone
    • Nathan Goodyear
      Nathan Goodyear on 12 May 14
       
      And if one would have looked at their estrogen levels, I guarantee they would have been found to be elevated.
  • low bioavailable testosterone and high SHBG were associated with a 4.9- and 3.2-fold risk of positive biopsy
  • Current EAU, ISSAM, and BSSM guidance [1, 2] is that there is “no evidence TRT is associated with increased risk of prostate cancer or activation of subclinical cancer.”
  • Men with prostate cancer, treated with androgen deprivation, develop an increase of fat mass with an altered lipid profile
  • Erectile dysfunction is an established marker for future cardiovascular risk and the major presenting symptom leading to a diagnosis of low testosterone
Nathan Goodyear

Testosterone 2% Gel Can Normalize Testosterone Con... [J Sex Med. 2013] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...24283410

testosterone gel therapy treatment men map hormone hormones low T

shared by Nathan Goodyear on 29 Nov 13 - No Cached
  • Nathan Goodyear on 29 Nov 13
     
    Study finds that transdermal testosterone effective in normal and overweight men.  The dosing involved is supra physiologic, especially those with an elevated BMI.  This was likely due to the high dosing to overcome the underlying problem i.e. high aromatase activity.  These studies all need to assess estrogens and inflammatory cytokines to better follow these results
Nathan Goodyear

Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial : The Lancet - 0 views

www.thelancet.com/...fulltext

CFS chronic fatigue syndrome hydrocortisone cortisol fatigue adrenal fatigue hypoadrenia adrenal insufficiency

shared by Nathan Goodyear on 01 May 12 - No Cached
  • Nathan Goodyear on 01 May 12
     
    low dose hydrocortisone therapy, 5-10 mg, shown to be effective short-term therapy in patients with chronic fatigue syndrome.  Additionally, and very important, this study found no adrenal function suppression at these doses.
Nathan Goodyear

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis - 0 views

www.neurology.org/...382

vitamin D MS multiple Sclerosis inflammation IL-17

shared by Nathan Goodyear on 25 Feb 16 - No Cached
  • Nathan Goodyear on 25 Feb 16
     
    High dose vitamin D (10,400 IU) found to reduce IL-17, CD161 and effector memory cells; in contrast low dose vitamin D (800 IU)  did not.  The study also called into question the traditional target range of vitamin D.  The authors here proposed 40-60
Nathan Goodyear

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis - 0 views

www.neurology.org/...WNL.0000000000002316

multiple Sclerosis MS vitamin D inflammation IL-17

shared by Nathan Goodyear on 07 Jan 16 - No Cached
  • Nathan Goodyear on 07 Jan 16
     
    Not only is high dose vitamin D3 therapy more effective in reducing IL-17 compared to low dose, but it is safe to in individuals with MS.  The hot topic these days is immunotherapy: that is exactly what vitamin D therapy is.
Nathan Goodyear

Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant tr... - PubMed - NCBI - 1 views

www.ncbi.nlm.nih.gov/...8023699

IL-2 melatonin immunotherapy cancer

shared by Nathan Goodyear on 31 May 18 - No Cached
  • Nathan Goodyear on 31 May 18
     
    high dose melatonin and low-dose IL-2 in wide variety of solid tumors found tumor regression in 17 of 82 patiens (21%).  Four of these were complete remission and 13 were Partial.
Nathan Goodyear

Relationship between Low Free Testosterone Levels and Loss of Muscle Mass : Scientific Reports : Nature Publishing Group - 0 views

www.nature.com/...srep01818.html

muscle men male hormone Testosterone free Testosterone low T low Testosterone

shared by Nathan Goodyear on 05 Mar 15 - No Cached
  • Our data confirm that a low FT level is a significant predictor of a risk for loss of appendicular muscle
  • Total lean mass is associated with bioavailable T in postmenopausal women
  • Further studies are needed to determine the role of androgens in preserving muscle mass in women
  • ...11 more annotations...
  • Approximately 1% to 2% of T in the blood exists as FT
  • appendicular muscle loss was significantly associated with low levels of FT
  • These results suggest that a threshold level of FT exists for muscle loss, rather than a dose-response relationship
  • In the previous cross-sectional and longitudinal studies of French and American men, no dose-response relationships were reported between T and muscle mass
  • A minimal serum level of FT may be needed to preserve muscle mass in men, regardless of race/ethnicity.
  • Our result is in line with previous studies that reported a relationship between low FT and low muscle mass in men
  • T stimulates protein synthesis and inhibits protein degradation in muscle cells
  • T also increases satellite cell replication and activation in older men
  • In this study, no significant association between TT levels and muscle loss were observed
  • Although a progressive decrease in TT levels with ageing is observed in middle-aged and elderly American men16, 17, the TT levels do not change during ageing in Japanese men
  • FT levels may be a good marker for the loss of muscle mas
  • Nathan Goodyear on 05 Mar 15
     
    study of Japanese men finds that low free Testosterone was a predictor of decrease in muscle mass.
Nathan Goodyear

Massive Doses of Vitamin C and the Virus Diseases - 0 views

www.seanet.com/...med_surg-1951-v103-n4-p101.htm

IV therapy IV C virus viral illness nutrition nutritional therapy

shared by Nathan Goodyear on 23 Jan 13 - No Cached
  • Nathan Goodyear on 23 Jan 13
     
    High dose IV vitamin C beneficial in viral illnesses.  This is a case study article, but it discusses how viral illnesses are associated with low vitamin C levels and how high dose vitamin C therapy benefits the immune activity against viral invaders.
Nathan Goodyear

Bisphenol A Promotes Human Prostate Stem-Progenitor Cell Self-Renewal and Increases In Vivo Carcinogenesis in Human Prostate Epithelium - 0 views

www.ncbi.nlm.nih.gov/...PMC3929731

BPA bisphenol A cancer prostate cancer prostate xenoestrogens

shared by Nathan Goodyear on 20 Apr 16 - No Cached
  • these findings show that estrogen stimulates human prostate epithelial stem cell self-renewal and progenitor cell amplification (prostasphere size), with the greatest effects observed at lower E2 doses.
  • Similar to E2, BPA increased prostasphere number and size with significant and maximal effects observed at 10 nM BPA
  • Taken together, these results provide strong evidence that, similar to E2, BPA increases stem cell self-renewal and progenitor amplification in normal human prostate epithelial cells
  • ...13 more annotations...
  • these findings provide further support that E2 and BPA maintain the stem-like state within the normal prostate epithelial cell population
  • Our previous findings demonstrated that normal prostate stem-progenitor cells within the prostaspheres expressed ERα and ERβ, implicating them as direct targets for E2 and BPA action
  • p-Akt and p-Erk, well established downstream targets of membrane-associated ERs
  • BPA and E2 had equimolar capacity for activation of these rapid signaling pathways in human prostaspheres, thus identifying a dynamic and robust signaling pathway initiated by low-dose BPA exposure in prostate stem-progenitor cells.
  • these findings indicate that both rapid membrane-initiated estrogen action and genomic ER signaling pathways are operative in human prostate progenitor cells.
  • these results document the fact that levels of bioactive BPA in the present study are similar to levels found in human umbilical cord blood and newborns in the general population
  • the present findings identify for the first time that in vivo exposure of the human prostate epithelium to low doses of BPA significantly increases the susceptibility of the human prostate epithelium to hormonal carcinogenesis.
  • The current study provides clear evidence that, similar to E2, normal human prostate stem and progenitor cells are direct targets for BPA action
  • Both hormones increased stem-like cell numbers in primary prostate epithelial cultures in a dose-dependent manner and augmented the number and size of 3-D cultured prostaspheres, markers of stem cell self-renewal and progenitor cell proliferation, respectively
  • signaling pathways engaged by estrogens through these separate receptors are multiple and complex, including both membrane-initiated signaling and genomic activation via ER transcriptional activity
  • Estrogen action is mediated by ERα and ERβ
  • the current results indicate that developmental exposure to BPA, at doses routinely found in humans, significantly increases the cancer risk in human prostate epithelium in response to elevated estrogen levels in an androgen-supported milieu. Because relative estrogen levels rise in aging men, we suggest that humans may be susceptible to BPA-driven prostate disease in a manner similar to that in the rodent models.
  • We propose that early-life perturbations in estrogen signaling including inappropriate exposure to BPA have the potential to amplify and modify the stem-progenitor cell populations within the human prostate gland and, in so doing, alter the normal homeostatic mechanisms that maintain a growth neutral state throughout life
  • Nathan Goodyear on 20 Apr 16
     
    Bisphenol A exposure in utero found to increase prostate cancer risk later in life.  This exposure occurred at typical life exposure levels as found in umbilical cord blood sampling,  This occurred through stem cell self-renewal and progenitor amplification
Nathan Goodyear

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer - 0 views

www.ncbi.nlm.nih.gov/...PMC6524297

cancer IV vitamin C vitamin C

shared by Nathan Goodyear on 30 Jul 19 - No Cached
  • Nathan Goodyear on 30 Jul 19
     
    IV vitamin C shown to be adjunctive with the chemotherapy regimens FOLFIRI and FOLFOX in colorectal and gastric cancer despite the therapeutic dose limited to 1.5 mg/kg/day, which is a low dose likely resulting in sub-therapeutic levels.
Nathan Goodyear

Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients - 0 views

www.ncbi.nlm.nih.gov/...PMC3751545

IV vitamin C dosing ascorbic acid inflammation disease cancer IV vitamin C intravenous vitamin C IV intravenous vitamin C vitamin C CRP therapy treatment alternative

shared by Nathan Goodyear on 26 Aug 14 - No Cached
  • Patients with higher tumor markers are likely to have higher tumor burden, higher oxidative stress and, therefore, are more likely to have lower post IVC plasma levels.
  • Our data also showed that cancer patients with metastasis tend to have lower post-IVC vitamin C levels than those without metastasis
  • Lower peak plasma concentrations are obtained in cancer patients than in healthy subjects. Cancer patients who are deficient in vitamin C prior to therapy tend to achieve lower plasma levels post infusion.
  • ...25 more annotations...
  • Patients with higher inflammation or tumor burdens, as measured by CRP levels or tumor antigen levels, tend to show lower peak plasma ascorbate levels after IVC.
  • Patients with metastatic tumors tend to achieve lower post infusion plasma ascorbate levels than those with localized tumors.
  • Meta-analyses of clinical studies involving cancer and vitamins also conclude that antioxidant supplementation does not interfere with the efficacy of chemotherapeutic regiments
  • Most of the prostate cancer patients studied, 75±19% (95% confidence), showed reductions in PSA levels during the course of their IVC therapy
  • Laboratory studies suggest that, at high concentrations, ascorbate does not interfere with chemotherapy or irradiation and may enhance efficacy in some situations
  • Cameron and Pauling observed fourfold survival times in terminal cancer patients treated with intravenous ascorbate infusions followed by oral supplementation
  • The inflammatory microenvironment of cancer cells leads to increasing oxidative stress, which apparently depletes vitamin C, resulting in lower plasma ascorbate concentrations in blood samples post IVC infusion. Another explanation for this finding may be that cancers are themselves more metabolically active in their uptake of vitamin C, causing subjects to absorb more of the vitamin, and as a results show lower plasma ascorbate concentrations in blood post IVC infusion.
  • patients with severely elevated CRP levels attain plasma ascorbate concentrations after IVC infusions that are only 65% of those attained for subjects with normal CRP levels
  • The finding of decreased plasma ascorbate levels in cancer patients may relate to the molecular structure of ascorbic acid; in particular, the similarity of its oxidized form, dihydroascorbic acid, to glucose
  • Since tumor have increased requirement for glucose [67], transport of dehydroascorbate into the cancer cells via glucose transport molecules and ascorbate through sodium-dependent transporter may be elevated
  • Increased accumulation of ascorbic acid in the tumor site was supported by measurements of the level of ascorbic acid in tumors in animal experiments
  • patients with advanced malignancies may have lower level of ascorbic acid in tissue, creating a higher demand for the vitamin C
  • IVC therapy appears to reduce CRP levels in cancer patients.
  • CRP concentrations directly correlate with disease activity in many cases and can contribute to disease progression through a range of pro-inflammatory properties.
  • Being an exquisitely sensitive marker of systemic inflammation and tissue damage, CRP is very useful in screening for organic disease and monitoring treatment responses
  • ncreases in CRP concentrations have been associated with poorer prognosis of survival in cancer patients, particularly with advance disease independent of tumor stage
  • Regarding inflammation, 73±13% of subjects (95% confidence) showed a reduction in CRP levels during therapy. This was an even more dramatic 86±13% (95% confidence) in subjects who started therapy with CRP levels above 10 mg/L
  • patients treated by IVC with follow-up several year showed that suppression of inflammation in cancer patients by high-dose IVC is feasible and potentially beneficial
  • Inflammation is a marker of high cancer risk, and poor treatment outcome
  • The subjects with highly elevated CRP concentrations have a three-fold elevation “all-cause” mortality risk and a twenty-eight fold increase in cancer mortality risk
  • cancer patients may need higher doses to achieve a given plasma concentration.
  • patients with lower vitamin C levels may see more distribution of intravenously administered ascorbate into tissues and thus attain less in plasma.
  • When treating patients with IVC, the first treatment likely serves to replenish depleted tissue stores, if those subjects were vitamin C deficient at the beginning of the treatment. Then, in subsequent treatments, with increasing doses, higher plasma concentrations can be attained. On-going treatments serve to progressively reduce oxidative stress in cancer patients.
  • large doses given intravenously may result in maximum plasma concentrations of roughly 30 mM, a level that has been shown to be sufficient for preferential cytotoxicity against cancer cells
  • oral intake of vitamin C exceeded 200 mg administered once daily, it was difficult to increase plasma and tissue concentrations above roughly 200 μM.
  • Nathan Goodyear on 26 Aug 14
     
    Great review on the use of IV vitamin C in cancer and to reduce inflammation.  The article does a great job of discussing the mechanism of vitamin C therapy in cancer as well as the proposed reasons for low vitamin C in cancer patients.  The study also highlights the obstacles to rise in vitamin C levels post IV vitamin C in cancer patients.
Nathan Goodyear

Low-Dose Naltrexone in Combination with High-Dose Vitamin C in Cancer Patients: Our Experience and Medical Literature Review - it should be Reinforced in Our Practices of Integrative Oncology - 0 views

LDN metastasis IV vitamin C vitamin C cancer High dose IV vitamin C dose high dose vitamin C low naltrexone)

shared by Nathan Goodyear on 09 Mar 21 - No Cached
  • Nathan Goodyear on 09 Mar 21
     
    Review of one clinics experience with HDIVC and LDN.
Nathan Goodyear

Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells - 0 views

maximum tolerated chemotherapy low-dose chemotherapy metronomic chemotherapy

shared by Nathan Goodyear on 04 Oct 20 - No Cached
  • Nathan Goodyear on 04 Oct 20
     
    Only pdf available here. Start difference in the MTD to metronomic dosing of chemotherapy.
Nathan Goodyear

Low-Dose Naltrexone Reduces the Symptoms of Fibromyalgia - Stanford Systems Neuroscience & Pain Lab - Stanford University School of Medicine - 0 views

snapl.stanford.edu/...ldn.html

low dose naltrexone LND pain inflammation fibromyalgia stanford

shared by Nathan Goodyear on 27 Nov 12 - No Cached
  • Nathan Goodyear on 27 Nov 12
     
    low dose naltrexone shown to reduce pain in those with fibromyalgia.  This is a very small study, though with positive results.
Nathan Goodyear

Oxycodone Plus Ultra-Low-Dose Naltrexone Attenuates Neuropathic Pain and Associated μ-Opioid Receptor-Gs Coupling - 0 views

www.jpain.org/...abstract

naltrexone pain control

shared by Nathan Goodyear on 19 May 11 - No Cached
  • The antihyperalgesic and antiallodynic effects of oxycodone plus ultra-low-dose NTX (Oxytrex, Pain Therapeutics, Inc., San Mateo, CA) suggest a promising new treatment for neuropathic pain.
  • Nathan Goodyear on 19 May 11
     
    low dose naltrexone plus opiate therapy improves neuropathic pain
Nathan Goodyear

Chronic exposure to Low dose bacterial lipopolysaccharide inhibits leptin signaling in vagal afferent neurons - 0 views

www.ncbi.nlm.nih.gov/...PMC4523075

LPS lipopolysaccharides leptin CCK cholecystokinin metabolism weight appetite diet nutrition inflammation

shared by Nathan Goodyear on 04 Oct 17 - No Cached
  • Obesity and models of obesity induced by ingestion of HF-diet in rodents are associated with chronically elevated circulating levels of LPS
  • chronic low-dose administration of LPS induces leptin-resistance in vagal afferent neurons and abolition of CCK-induced inhibition of food intake
  • HF fat feeding has been shown to enhance gastrointestinal permeability promoting the translocation of LPS to the circulation
  • ...9 more annotations...
  • LPS leads to an increase in SOCS3 expression [20]. SOCS3 is a negative regulator of leptin signaling
  • We observed a significant increase in energy intake in the LPS-treated rats
  • the data provides a mechanism linking changes in gut microbiota induced by ingestion of HF diets to dysregulation of food intake and body weight
  • SOCS3 is an important mechanism by which leptin resistance develops in vagal afferent neurons and coincides with the onset of hyperphagia
  • Chronic low-dose LPS treatment induced TLR4 activation and MyD88 signaling in vagal afferent neurons, associated with increased SOCS3 expression and reduced leptin-signaling, characterized by the absence of leptin-induced pSTAT3.
  • We demonstrate that this chronic low dose LPS is sufficient to induce leptin–resistance in vagal afferent neurons, reduced sensitivity to the satiating effects of CCK, and loss of vagal afferent plasticity
  • it suggests that the increase in food intake and body weight we observed at week 6 in the LPS treated rats may be caused by LPS-induced leptin resistance.
  • chronic LPS treatment of mice for four weeks increased body weight
  • chronic LPS treatment of mice for four weeks increased subcutaneous fat
  • Nathan Goodyear on 04 Oct 17
     
    Very interesting study.  High fat diet in rats induced gut flora change that resulted in LPS which induced appetite through leptin resistance and reduced cholecystokinin signaling.
Nathan Goodyear

Combined treatment with vitamin C and methotrexate inhibits triple-negative breast cancer cell growth by increasing H2O2 accumulation and activating caspase-3 and p38 pathways - 0 views

www.spandidos-publications.com/...or.2017.5439

IV vitamin C breast cancer EGFR triple negative breast cancer vitamin C TNBC Caspase-3 methotrexate

shared by Nathan Goodyear on 15 Mar 21 - No Cached
  • Nathan Goodyear on 15 Mar 21
     
    Low dose methotrexate + low dose vitamin C inhibit TNBC via EGFR mechanism
‹ Previous 21 - 40 of 322 Next › Last »
Showing 20▼ items per page